Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS FE 1/20 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (for females ≥15 years old who have menarche and desire contraception),Oral contraceptive for women with iron deficiency anemia (as Gildess Fe 1/20 contains ferrous fumarate)
Prevention of pregnancy
One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: terminal half-life approximately 13 hours (range 10-15 h). Desogestrel: metabolized to etonogestrel; etonogestrel terminal half-life about 28 hours (range 20-40 h). Clinical context: steady-state reached within 7-10 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation; norethindrone is reduced and conjugated via glucuronidation and sulfation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Approximately 60-65% renal (as metabolites), 30-35% fecal (as metabolites and unchanged drug). Ethinyl estradiol and desogestrel metabolites are excreted primarily via urine and feces. Etonogestrel (active metabolite) is excreted mainly via feces (40%) and urine (32%).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: 97-98% bound to albumin, with specific binding to sex hormone-binding globulin (SHBG). Etonogestrel: >95% bound, primarily to albumin (60-70%) and SHBG (30-40%).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: apparent Vd approximately 2.5 L/kg (range 2.1-3.0 L/kg). Desogestrel: Vd for etonogestrel is about 2.0 L/kg. High Vd indicates extensive tissue distribution, including adipose and reproductive tissues.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Ethinyl estradiol bioavailability approximately 45-55% due to first-pass metabolism (sulfation and glucuronidation). Desogestrel: prodrug, bioavailability of etonogestrel is about 76-84% after oral dose. No other relevant routes.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential for fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in severe hepatic impairment (Child-Pugh class C). Caution in moderate impairment (Child-Pugh class B) due to altered hormone metabolism; use alternative methods if possible.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Approved for postmenarchal adolescents; dosing same as adults: one tablet orally once daily for 21 days followed by 7 placebo tablets.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not typically indicated for postmenopausal women due to ineffectiveness; if used in appropriate patients, no dose adjustment required but monitor for thromboembolic risks.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (≥15 cigarettes/day) and is significant in women >35 years old. Women >35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, stroke, MI),Carcinoma of the breast and reproductive organs,Hepatic disease (adenoma, hepatocellular carcinoma),Ocular lesions (retinal thrombosis),Gallbladder disease,Carbohydrate and lipid effects,Elevated blood pressure,Headache/migraine,Bleeding irregularities,Depression,Hereditary angioedema,Chloasma,Hepatic function impairment,Iron supplementation (Fe fumarate): may cause GI upset, constipation, and dark stools
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Benign or malignant liver tumor,Active liver disease,Hypersensitivity to any component,Smoking in women >35 years
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. However, grapefruit juice may inhibit CYP3A4 metabolism and theoretically increase estrogen levels, but clinical significance is undetermined. Avoid St. John's wort, which reduces contraceptive efficacy. Caffeine metabolism may be decreased, leading to increased caffeine effects. No specific dietary restrictions required.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestin component. Second and third trimesters: Risk of fetal feminization (masculinization of female fetuses) from androgen-like effects of progestin; also associated with increased risk of neonatal hepatoblastoma and possibly other tumors. Combination hormonal contraceptives should be discontinued immediately if pregnancy occurs.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk in small amounts (estrogen and progestin). M/P ratio not well-defined. Use may reduce milk production and quality, especially in early postpartum period. Consider alternative contraception during breastfeeding, especially in first 6 months. Use only if benefits outweigh risks, with close monitoring of infant growth and development.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dose adjustments indicated as use is not recommended. If inadvertently taken during pregnancy, discontinue immediately. No dosage changes are suggested for postpartum use, but alternative contraception should be considered during breastfeeding.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Gildess FE 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate with ferrous fumarate placebos. It is indicated for contraception and may be used off-label for acne. The low estrogen dose may lead to more breakthrough bleeding, especially in the first few cycles. Advise patients to take at the same time daily and not to skip active pills. The iron in placebos can cause dark stools; warn patients. Missed pill management: if one active pill is missed, take it as soon as remembered; if two are missed, take two and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) which reduce efficacy. Not recommended in patients with BMI > 35 due to increased failure risk. Do not use in smokers over 35 years old. Monitor blood pressure and for thrombotic events.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time, even during withdrawal bleed weeks.,If you miss a pill, follow the package instructions: take the missed pill immediately and continue; if more than one missed, use backup contraception for 7 days.,The last 7 pills in the pack are placebo; they contain iron, so do not skip them but they don't provide contraceptive protection.,Iron in placebos may cause dark stools; this is harmless.,Common side effects: nausea, breast tenderness, headache, breakthrough bleeding (especially first 3 months). These often improve with time.,Contact your doctor if you have severe abdominal pain, chest pain, shortness of breath, severe headaches, vision changes, or leg pain/swelling.,This pill does not protect against sexually transmitted infections (STIs). Use condoms for STI prevention.,Avoid smoking while taking this medication, especially if over 35 years old.,Tell your doctor about all medications, especially antibiotics, antifungals, and seizure medications, as they may decrease effectiveness.,If you are undergoing surgery, inform your surgeon you are taking this pill.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS FE 1/20 vs ALYACEN 7/7/7, answered by our medical review team.
GILDESS FE 1/20 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release; norethindrone induces progestational changes in endometrium and cervical mucus, preventing ovulation and fertilization.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS FE 1/20 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS FE 1/20 is: One tablet orally once daily for 21 days followed by 7 placebo tablets per 28-day cycle.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS FE 1/20 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS FE 1/20 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reducti. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.